GRCE
GRCE clinical trials: Grace Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Grace Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 8
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
GRCE on the catalyst calendar · GRCE registry changes
- Primary completion Dec 2024Sponsor estimatePhase 3NCT05995405Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAHGrace Therapeutics Inc. · Aneurysmal Subarachnoid Hemorrhage (aSAH)Active, not recruitingGRCELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2022ActualPhase 1NCT05418348Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy SubjectsGrace Therapeutics Inc. · Aneurysmal Subarachnoid HemorrhageCompletedGRCELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2022ActualPhase 1NCT05531890Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy SubjectsGrace Therapeutics Inc. · Ataxia TelangiectasiaUnknown statusGRCELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 21, 2022ActualPhase 1NCT05517486Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy SubjectsGrace Therapeutics Inc. · Postherpetic NeuralgiaUnknown statusGRCELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 24, 2019ActualPhase 3NCT03361501A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)Grace Therapeutics Inc. · HypertriglyceridemiaCompletedGRCELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2019ActualPhase 3NCT03398005A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)Grace Therapeutics Inc. · HypertriglyceridemiaCompletedGRCELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2014ActualPhase 2NCT01455844TRIal For Efficacy of Capre on hyperTriglyceridemiAGrace Therapeutics Inc. · HypertriglyceridemiaCompletedGRCELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2013ActualPhase 2NCT01516151Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high HypertriglyceridemiaGrace Therapeutics Inc. · HypertriglyceridemiaCompletedGRCELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner